Litigation News

E3D Online revised its patent policy to target commercial infringement while maintaining free use for hobbyists and researchers. The Oxford-based 3D printer components manufacturer holds patents covering Revo hotend, Squeezetube, and ObXidian technologies in UK, Europe, China, and US. E3D secured IP management, infringement insurance, and board-level litigation funding. The company encourages licensing arrangements and warns commercial users of potential enforcement action extending to importers and distributors in key markets.

Six individuals including former Samsung Electronics IP Center employee and NPE CEO indicted for leaking $5 million worth of patent secrets. Former Samsung engineer received $1 million for providing confidential patent analysis data and negotiation strategies to NPE between 2021-2023. NPE used stolen information to secure $30 million patent contract with Samsung. Seoul Central District Prosecutors charged defendants with Unfair Competition Prevention Act violations, bribery, and breach of trust. Case highlights growing NPE threats against Korean tech companies.

Amazon and InterDigital are involved in a patent dispute that has prompted a landmark referral to the Court of Justice of the European Union (CJEU). A UK court ruling emphasized the need for improved cross-court communication, while the Unified Patent Court (UPC) has asked Europe's highest court to clarify rules regarding long-arm jurisdiction. The case highlights jurisdictional complexities in European patent litigation proceedings.

Former Samsung Electronics IP Center employee indicted for leaking confidential patent analysis materials to NPE "patent troll" company in exchange for $1 million. Seoul Central District Prosecutors' Office charged the employee and NPE representative with trade secret violations and bribery. The leaked materials helped NPE secure $30 million patent contract with Samsung Electronics. Additional charges include document forgery and involvement of other Samsung employees in transmitting confidential information.

AMD and Adeia Inc signed a multi-year licensing agreement granting AMD access to Adeia's semiconductor intellectual property portfolio, including technologies related to hybrid bonding, semiconductor packaging, and processing. The agreement resolves all ongoing litigation between the companies, allowing both to move forward and potentially explore future collaboration on advanced semiconductor technologies.

U.S. District Court for the District of Delaware published proposed local rule revisions on February 25, with comment period until April 25. Key changes include new patent case requirements for attaching re-examination certificates, new arbitration award proceedings rule, clarified double-spacing format requirements, streamlined motion briefing procedures, consent motion blacklining requirements, extended cost taxation deadlines, and updated bar admission requirements for out-of-state Delaware-admitted attorneys. Most revisions formalize existing standard operating procedures in the district.

Brazil's antitrust authority is demanding detailed explanations from Ericsson and Motorola regarding their global litigation strategies in a 5G patent dispute. The companies believed the matter was resolved in April 2025, but Brazilian regulators are now scrutinizing their worldwide patent enforcement tactics. The authority is pressuring both telecommunications companies to justify their litigation approaches in this ongoing intellectual property conflict over 5G technology patents.

Novo Nordisk dismissed its patent infringement lawsuit against Hims & Hers following an agreement allowing the telehealth platform to sell Novo's weight-loss drugs. The pharmaceutical company reserved rights to pursue future legal action if needed. The settlement enables Hims & Hers to distribute Novo's obesity medications through its digital health platform, resolving the intellectual property dispute between the companies.

Novo Nordisk dropped its patent infringement lawsuit against Hims & Hers over compounded Wegovy sales. Under the settlement, Hims agreed to stop advertising compounded GLP-1 products and will offer brand-name Wegovy on its platform. However, Hims can continue providing compounded versions when clinically necessary. Novo reserves the right to refile the lawsuit in the future, suggesting the dispute may not be permanently resolved.

Novo Nordisk dropped its patent lawsuit against telehealth company Hims & Hers and struck a partnership deal instead. The lawsuit stemmed from Hims selling a copycat Wegovy pill for $49, undercutting Novo's branded version by $100. Under the settlement agreement, Hims will sell Novo's branded weight loss medications including Ozempic and Wegovy, while agreeing to stop advertising compounded GLP-1 drugs and reserve compounding only for medically necessary cases.